Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety of iodixanol 300 in elderly patients
ChiCTR2400093400Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Harbin Medical University
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iodixanol in Adverse reaction to iodinated contrast media (ARICM), sponsored by The Fourth Hospital of Harbin Medical University. Primary endpoints: Incidence and characteristics of acute adverse reactions, Incidence and characteristics of delayed adverse reactions and 2 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
iodixanol
03
Conditions
Adverse reaction to iodinated contrast media (ARICM)
Beyond the preview
Go deeper on ChiCTR2400093400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093400.